MedTrace Logo

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

NCT05889741 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-09-04

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Ropivacaine injection

6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion

DRUG

Normal saline

6.5cc of Normal Saline one time into the stellate ganglion.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Alan Peterson, PhD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-26
Primary Completion
2027-03-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889741 on ClinicalTrials.gov